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INTRODUCTION
Menopause is defined as a woman who stops men-
struating at the age of 51 to 65 years for more than
12 months spontaneously and the level of follicle
stimulating hormone (FSH) blood was >40mIU/ml
and estradiol level was <30 pg/ml.1
Research in Netherland shows the mean age of
menopause was 50.2 years. Approximately 1% of
women experience premature menopause before
the age of 40 years and 1% of women experience
menopause at the age of 58 years.2 Research on
Women’s Health Across the Nation shows the
mean age of menopause was 51.4 years. The mean
age of menopause is 45 years old accompanied by
increasing of hormone estradiol in perimenopausal
period is one year before the on set of menopause.
In developing countries the average age of female
menopause occurs earlier than the western coun-
tries. Research in Indonesia showed the average
age of menopause is 48 to 49 years. Research in
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Objective: To determine the correlation between length of meno-
pause with C-telopeptide in pascamenopause women.
Method: An analytic cross-sectional study of 29 pascamenopause
women in Malalayang hospital Manado. Sampling method with con-
secutive random sampling. Data were analyzed with Spearman test
with significance level of p<0.05.
Result: Among of 29 pascamenopause women with a mean of age
58.62 ± 4.694  years. Mean of length of menopause is 8.76 ± 5.520
years with median 7 years (quartil 5.00 until 11.5 years). Mean of
C-telopeptide plasma level is 0.524 ± 0.256 μg/l with median 0.472
μg/l (quartil 0.324 until 0.656 μg/l). We found length of menopause
and C-telopeptide plasma level were not distributed normal
(p<0.05). Correlation analysis by Spearman found significant posi-
tive correlation between length of menopause and C-telopeptide
plasma level.
Conclusion: There is significant positive correlation between C-
telopeptide plasma level with length of menopause in pascameno-
pause women.
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Abstrak
Tujuan: Mengetahui korelasi antara lama menopause dengan kadar
C-telopetide plasma perempuan pascamenopause.
Metode: Penelitian ini merupakan studi potong lintang analitik yang
mengikutsertakan 29 perempuan pascamenopause secara consecu-
tive sampling yang kontrol di poliklinik bagian kebidanan dan kan-
dungan RS Malalayang Manado secara sukarela yang dinyatakan
dengan informed consent. Analisis data menggunakan uji Spearman
dengan tingkat kemaknaan p<0,05.
Hasil: Dari 29 perempuan pascamenopause dengan rerata usia 58,62
± 4,694 tahun. Rerata lama menopause adalah 8,76 ± 5,520 tahun
dengan median 7 tahun (nilai kuartil 5,00 sampai 11,50 tahun). Re-
rata kadar C-telopeptide adalah 0,524 ± 0,256 μg/l dengan median
0,472 μg/l (nilai kuartil 0,324 sampai 0,656). Data lama menopause
dan C-telopeptide tidak berdistribusi normal (p<0,05) sehingga untuk
mengetahui hubungan antara lama menopause dengan kadar C-te-
lopeptide digunakan analisis korelasi Spearman. Hasil analisis korelasi
antara lama menopause dengan kadar C-telopeptide didapatkan nilai
r = 0,485 dengan nilai p = 0,008. Hal ini menunjukkan bahwa terdapat
hubungan positif antara lama menopause dengan kadar C-telopeptide
secara bermakna (p<0,05).
Kesimpulan: Terdapat hubungan positif bermakna antara lama
menopause dengan kadar C-telopeptide.
[Maj Obstet Ginekol Indones 2014; 2: 82-86]
Kata kunci: kadar C-telopeptide plasma, lama menopause, perempu-
an pascamenopause.
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Bitung found that climacterium woman was in the
age range 40 to 55 years with a mean age of me-
nopause 48 years.2,3
Presence of metabolic and hormonal change is
a result of menopause, which one of the hormonal
changes is osteoporosis. Osteoporosis is a metabo-
lic bone disease characterized by decreased bone
mass due to reduced bone mineral matrix and ac-
companied by destruction of bone tissue micro ar-
chitecture that result in decreased bone strength
resulting in a tendency to bone fracture.4 In osteo-
porosis the bone remodeling abnormalities also oc-
cur where the process of bone resorption (bone re-
sorption) more than the process of bone formation
(bone formation), where the cells responsible for
bone formation while osteoclasts are called osteo
blasts are responsible for bone resorption.1,2,4-6
The incidence of osteoporosis increases with in-
creasing aging population.7 Some literature sug-
gests that menopausal women have a significantly
higher risk for osteoporosis occurs, in which the
ratio of the tendency to suffer from primary os-
teoporosis in women: men is 5:1. In women aged
over 50 years found 30% of osteoporosis, osteo-
penia 37 to 54% and 54% higher risk of osteo-
porotic fracture. Research shows that osteoporosis
affects 44 million Americans or 55% of the popu-
lation above 50 years of age. The prevalence of
osteoporosis in women aged over 50 years in In-
donesia is 34%.8 Research Ketia et al., 2006
showed the prevalence of osteoporosis in women
was 91.7% with a mean age of 66.36 ± 11.74 years.
Approximately 35% of postmenopausal women
will suffer from osteoporosis, and 50% will have
osteopenia.9
Bone consists of bone matrix containing 90%
collagen (Type-1 Collagen contains N-telopeptides,
C-telopeptides and deoxypyridinolines), 10% pro-
tein (osteocalcine, osteonectin, osteopontin), bone
mineral (calcium and phosphate) and bone cells
(osteoclasts, osteo blasts and lining cells). Process
off or mation and bone resorption are in balance
when individuals aged 30 to 40 years. In normal
physiological remodeling process, bone is an organ
that always have the turn over, which is a balance
process between resorption and formation happen
continuously. This balance process of the forma-
tion and absorption began to fail and bone resorp-
tion process more likely occur when women reach
menopause and men reach the age of 60 years. In-
creased bone resorption process than bone forma-
tion in postmenopausal women is caused by a de-
ficiency of the hormone estrogen which would then
stimulate the release of mediators that influence
the activity of osteoclasts. So that plays a role in
the occurrence of osteoporosis directly is the num-
ber and activity of osteoclasts is influenced by me-
diators, which the mediators is greatly influenced
by the level of the hormone estrogen.10
Correlation between C-telopeptide level with os-
teoporosis had been reported. Research in Manado
showed that there were significant correlation bet-
ween the level of estrogen, IL 6, and C-telopeptide,
which is considered to be mutually influential va-
riables in the occurrence of physiological changes
in perimenopausal women. This study also showed
increasing rate of bone resorption followed by in-
creasing age, C-telopeptide level and decreasing of
estrogen level.11
Some the ories shows that differentiation and
activity of osteoclasts increased the estrogen de-fi-
ciency. Under normal circumstances estrogen in
circulation reached osteo blast cells and move
through receptors in the cell cytosol resulted in a
decreased secretion of cytokines such as interleu-
kin-I (IL-1), interleukin-6 (IL-6) and Tumor Necro-
ting Factor Alpha (TNF-α) in which this cytokine
function for bone resorption. Estrogen also increa-
ses the secretion of Transforming Growth Factor β
(TGF-β) which is the only growth factor (growth
factor) which is a mediator to attract osteo blasts
to the bone hole that has been absorbed by osteo-
clasts. Osteo blast cells are the main target cells of
estrogen to releases everal growth factors and cy-
tokines. Estrogen effects on osteoclasts have an im-
pact both directly and indirectly. Direct effect of es-
trogen is to prevent the differentiation of osteo-
clasts precurs or cells and suppress activation of
matur eosteoclasts. While the influence of estrogen
will indirectly affect the process of differentiation,
activation and apoptosis of osteoclasts. In the dif-
ferentiation and activation of estrogen suppresses
the expression of RANK-Ln, M-CSF on osteo blasts
and stromal cells prevent the complex bond bet-
ween RANK-L and OP Greceptors by producing
competing with RANK.4,5,12
Examination of bone biochemical markers of
bone remodeling activity has been carried out. Se-
veral biochemical markers of bone metabolism in-
clude bone alkaline phosphatase, osteocalcine,
bone Glaprotein (BGP) and C-telopeptide. Several
cross-sectional studies showed that bone turn over
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increases rapidly after menopause women age
where there is an increase in level of osteocalcin
and bone alkaline phosphatase by 50% and in-
creased level of C-telopeptide by 50% to 150%. C-
telopeptide a specific protein is a biochemical in-
dicator to show the process of bone resorption ac-
tivity of osteoclasts in bone. Molecular C-telopep-
tide and bone-specific to a cluster of amino acids
to detect the activity of osteoclasts. C-telopeptide
examination can be done by ELISA (enzyme-linked
immuno-absorbent assays) of serum or urine.
Lateef study, 2009 showed elevated level of serum
C-telopeptide were significantly increased in post-
menopausal women with osteoporosis and without
osteoporosis. Increased serum level of C-telopep-
tide was significant in premenopausal women with
level more than 0.573ng/ml would increase the
risk off racture is 2-6 times higher bone degrada-
tion.13
Research Eastell et al., 2007 showed that ele-
vated level of markers of bone formation and bone
destruction increases according to age and this
process continues until a woman enters a period
of 80 years of age or have experienced menopause
for 40 years.
Although osteoporosis is not a new problem but
the problems currently faced by women experien-
cing menopausal osteoporosis is not only a decline
in the quality and function of living in creases mor-
bidity and mortality, but treatment is complicated
by osteoporosis who fracturea difficult thing that
takes a long time and considerable cost. In osteo-
porosis accompanied by complications will cause
serious morbidity and mortality.14
Due to there was not data about correlation bet-
ween length of menopause with C-telopeptide in
pascamenopause women in Manado encourage re-
searchers to conduct this research.
METHODS
This study is a cross-sectional analytic study per-
formed on 29 patients in Malalayang hospital Ma-
nado on April 2013 with consecutive random sam-
pling method.
C-telopeptide examination conducted at the La-
boratory Prodia Manado. Blood sampling perfor-
med after the study participants under went fast-
ing for 12 hours. Blood was drawn at 0.5cc (0.3 cc)
and inserted into the test tubes containing the anti
coagulant agent (heparin/EDTA) when inserted in-
to the plasma serum sodium heparin; stabilized at
a temperature of 2-25°C for 24 hours, or -20°C for
3 months, or at -70°C for 3 months. If EDTA plasma
serum plasma included in the stabilization of the
serum is at a temperature of 20-25°C for 24 hours;
4-8°C for 8 days.
Inclusion criteria in this study were post-
menopausal patients aged between 51 to 65 years
and willing to participate in this study voluntarily
stated to informed consent. While the exclusion cri-
teria were a history of previous fractures, partici-
pant same norrhoe as in ceremoval of the uterus
or ovaries, a history of breast cancer, endometrial
cancer and ovarian cancer, women who have pre-
viously been diagnosed with osteoporosis, treat-
ment for osteoporosis therapy (bisphosphonates,
vitamin D, calcitonin, fluoride, hormone replace-
ment therapy, calcium supplements).
RESULTS
Characteristics of Subjects
Distribution of subject characteristics based on age,
weight, duration of menopause, and level of C-
telopeptide was shown in Table 1.
Table 1. Characteristics of Subjects.
N Min Max Mean Std. Deviation
Age 29 52 65 58.62 4.694
Weight 29 40 75 56.52 10.555
Long menopause 29 2 24 8.76 5.520
C-Telopeptide 29 .186 1.190 .52448 .255876
Of the 29 subjects were postmenopausal women
with mean age was 58.62 ± 4.694 years. The mini-
mum age of 52 years and maximum age 65 years.
The mean body weight was 56.52 ± 10 555 kg with
a minimum weight of 40 kg and a maximum weight
of 70 kg. For the mean time of menopause was 8.76
± 5.520 in the shortest menopause is 2 years old
and the longest is 24 years old menopause. The
mean level of C-telopeptide was 0.524 ± 0.256
mg/l.
Further more, normality test was performed on
the length of menopause and C-telopeptide level to
determine the distribution of the data. Based on
the results of normality test, it is shown that both
variables were not distributed normally.
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Spearman correlation test was performed to de-
termine the correlation between the length of me-
nopause with C-telopeptide level (shown in Table
3), showed that the value of r=0.485 with p=0.008
(p<0.005). This shows that there is a positive rela-
tionship between length of menopause with C-
telopeptide level were significantly which means
that the longer duration of menopause, the greater
of C-telopeptide level (p<0.05).
Figure 1 shows that a significant positive corre-
lation between duration of menopause with level
of C-telopeptide. The longer duration of, the grea-
ter of C-telopeptide level.
DISCUSSION
Subjects were postmenopausal women who are
willing to participate and fulfill the inclusion crite-
ria of research conducted in the department of
Malalayang Manado. Characteristic subject are
shown in Table 1 with theme an age of post-
menopausal women was 58.62 ± 4.6 94 years old.
The mean of menopause duration was 8.76 ± 5.5
20 years, with the shortest period was 2 years and
the longest was 24 years old. Research by Kawana
et al. Showed that the mean age of postmenopausal
women was 55.3 ± 3.7 years.14 Research by Piedra
et al. Showed that the mean age of post meno-
pausal women was 56 ± 7 years.15 Research Taka-
hashi et al. showed a mean age of postmenopausal
women was 54.9 ± 3.6 years.16
The mean level of C-telopeptide in postmeno-
pausal women was 0.524 ± 0.256 mg/l. Research
by Kawana et al. showed the mean level of C-
telopeptide in postmenopausal women (2527 ±
      Table 2. Normality Tests.
Tests of Normality
Kolmogorov-Smirnova Shapiro-Wilk
Statistic Df Sig. Statistic Df Sig.
Long menopause .210 29 .002 .863 29 .001
C-telopeptide .148 29 .102 .907 29 .015
Table 3. Spearman Correlation Tests.
Correlations Long Menopause C-Telopeptide
Spearman’s rho Long Menopause Correlation Coefficient .485**
Sig. (2-tailed) .008
N 29
C-Telopeptide Correlation Coefficient .485**
Sig. (2-tailed) .008
N 29
** Correlation is significant at the 0.01 level (2-tailed)
* Correlation is significant at the 0.05 level (2-tailed)
Figure 1. Graphic of correlation between the Duration of
Menopause with C-Telopeptide Level in Postmenopausal
Women.
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1507 pm ol/l) was found higher than premeno-
pausal women (1345 ± 764 pm ol/l) with (p
<0.05).14 This suggests that elevated level of C-
telopeptide as an indicator of bone resorption as-
sociated with menopause. Research Piedra et al.
showed higher level of C-telopeptide in post-
menopausal women obtained 119 ± 66 mg/m
mol.15 Research Takahashi et al. Show α C-telopep-
tide level (382 ± 208 mg/mmol) was higher than
premenopausal 99 ± 186 mg/mmol (p<0.05).16
Spearman’s test showed that the correlation coe
eficient (r) between the duration of menopause
and the level of C-telopeptide was 0.485 with
p=0.008 (p<0.05). This suggests that there is a
positive correlation between duration of meno-
pause with C-telopeptide level. Research conducted
in Pakistan found a positive correlation between
C-telopeptide with age.16 Based on research con-
ducted in Manado in 2010 showed the increasing
age and decreasing level of estrogen menopausal
women with increasing level of C-telopeptide.11 Re-
search Garnero et al. shows with increasing time
post-menopause cause changes in bone mineral
density in postmenopausal bone so that examina-
tion plays an important marker for assessing the
risk of osteoporosis in postmenopausal women.17
In contrast research Takahashi et al. as many as
102 subjects who tuck postmenopausal women
with an age range between 46-90 years found no
significant correlation between level of C-telo-
peptide with α long menopause (r=0.11 with
p=0.3973). In the post-menopause women α C-
telopeptide level higher than premenopausal ob-
tained. Upon entering the postmenopausal state α
C-telopeptide level obtained continued to increase
until 43 years after menopause but elevated level
of C-telopeptide α urine samples more than the
minimum level of C-telopeptide of serum samples.
C-telopeptide can be used for indicators of bone
resorption time of growth, and the state of post-
menopausal osteoporosis in postmenopausal wo-
men.16,17
CONCLUSIONS
From these results it can be concluded that there
is a significant relationship between the duration
of menopause with increasing value of C-telopep-
tide. C-telopeptide as a biomarker to determine
bone loss as the risk of osteoporosis and assess the
success of treatment of osteoporosis in postme-
nopausal women.
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